Brand names: Cesamet
Nabilone capsules
What are Nabilone capsules?
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:How should this medicine be used?
What if I miss a dose?
What drug(s) may interact with Nabilone?
What should I watch for while taking Nabilone?
What side effects may I notice from receiving Nabilone?
Side effects that you should report to your prescriber or health care professional as soon as possible:Where can I keep my medicine?
Keep out of the reach of children in a container that small children cannot open.Last updated: 5/30/2006 1:55:00 PM
Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.
| Nystaform-HC, Nystaform, Nuvelle Continuous | |
| nabumetone, nadolol, nafarelin |
A synthetic cannabinoid used in the treatment of nausea and vomiting associated with cancer chemotherapy.
| Systematic (IUPAC) name | |
|---|---|
| (6aR,10aR)-rel-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)- | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607048 |
| Pregnancy cat. | C (US) |
| Legal status | Schedule II (US) |
| Routes | Oral form (PO)- capsule |
| Pharmacokinetic data | |
| Bioavailability | 20% after first-pass by the liver |
| Protein binding | similar to THC (+/-97%) |
| Half-life | 2 hours, with metabolites around 35 hours. |
| Identifiers | |
| CAS number | 51022-71-0 |
| ATC code | A04AD11 |
| PubChem | CID 5284592 |
| DrugBank | DB00486 |
| ChemSpider | 4447641 |
| UNII | 2N4O9L084N |
| KEGG | D05099 |
| ChEMBL | CHEMBL947 |
| Chemical data | |
| Formula | C24H36O3 |
| Mol. mass | 372.541 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Nabilone is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It is a synthetic cannabinoid, which mimics the main chemical compound of cannabis (THC). Chemically, nabilone is similar to the active ingredient found in naturally occurring Cannabis sativa L. [1]
In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the U.S. Food and Drug Administration (FDA) for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS.
Although it doesn't have the official indication (except in Mexico), nabilone is widely used as an adjunct therapy for chronic pain management. Numerous trials and case studies have demonstrated various benefits for conditions such as fibromyalgia[2] and multiple sclerosis.[3]
Nabilone is a racemic mixture consisting of the (S,S) and the (R,R) isomers ("trans").
The main settings that have seen published clinical trials of nabilone include movement disorders such as Parkinson's syndrome, chronic pain, dystonia and spasticity neurological disorders, fibromyalgia, multiple sclerosis, and the nausea of cancer chemotherapy. Nabilone is also effective in the treatment of inflammatory bowel disease, especially ulcerative colitis. Medical marijuana patients report that nabilone is more similar in effect to CBD than THC, indicating that it has more of a therapeutic effect on the body than a "high" effect on the mind.
A study comparing nabilone with metoclopramide, conducted before the development of modern 5-HT3 antagonist anti-emetics such as ondansetron, revealed that patients taking cisplatin chemotherapy preferred metoclopramide, while patients taking carboplatin chemotherapy preferred nabilone to control nausea and vomiting. [4] Another study compared nabilone alone to nabilone with dexamethasone. The study found that the combination worked better than the single medication. [5] An older study revealed that nabilone was more effective than prochlorperazine in controlling nausea, though in this study, only 9% of nabilone patients had complete resolution of symptoms. [6] A follow-up to this study revealed similar findings. [7]
One study compared the efficacy and tolerability of nabilone with that of dihydrocodeine in the treatment of neuropathic pain.[8] The authors found that nabilone was not as effective as dihydrocodeine in controlling pain, and caused a higher incidence of minor adverse drug reactions than did dihydrocodeine. One critic of the study has suggested that nabilone might be best suited for the treatment of patients suffering from central and spasticity-related pain, for which there is stronger evidence for the benefits of cannabinoid therapy; however, these patients made up only a small fraction of the study's population, and the study was not designed to identify subgroups which might have responded more favorably to treatment than others.[9]
A clinical trial performed in Canada reviewed the use of nabilone to treat nightmares in individuals suffering from post-traumatic stress syndrome[10]. The study found that nighttime administration of nabilone reduced the frequency and/or intensity of nightmares in 34 out of 47 (72%) of patients, with 28 reporting complete cessation of nightmares[10]. This study is limited to the extent that there was no placebo control, but warrants future investigation into the use of cannabinoid therapy in the treatment of post-traumatic stress syndrome and other disorders involving recurrent nightmares. As endocannabinoids play a significant role in regulating long-term depression, perhaps downregulating the CB1 system can help remove the highly potentiated, hippocampal/amydygalia memories of the fear. At the very least, CB1 agonists make one less likely to remember a dream, or even make REM sleep happen without significant involvement of the limbic system.
|
|||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)